We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Expert: FDA Unlikely to Approve More Biogenerics Without Industry Pressure
Expert: FDA Unlikely to Approve More Biogenerics Without Industry Pressure
June 12, 2006
Drug companies that want to market follow-on biologics will have to face off with the FDA in court if they want to get the agency to approve more products like Sandoz’ recombinant human growth hormone Omnitrope, according to one patent attorney.